AKT1 and osteosarcoma: Many preclinical studies have confirmed the efficiency of PI3K/AKT/mTOR pathways-targeted chemicals on chemo-resistant osteosarcoma; however, only a few mTOR-targeted compounds succeeded in entering clinical trials currently.